Piramal Pharma Solutions Press Releases

Piramal Enterprises acquires Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc.

Mumbai, 16th January, 2015: Piramal Enterprises Limited (‘PEL’, NSE: PEL, BSE: 500302) today announced that it has invested USD 30.65 million towards acquiring Coldstream Laboratories Inc. (‘Coldstream’), through its wholly owned subsidiary in the USA in an all cash transaction.  Of this, USD 5.65 million would be towards the purchase of the facility building which is currently leased to Coldstream, while the rest would be towards purchase of 100% of the company’s shares. Coldstream is a Contract Development and Manufacturing Organisation (CDMO) focused on the development and manufacturing of sterile injectable products.


Coldstream was founded in 2007 and is majority owned by University of Kentucky Research
Foundation (an affiliate of the University of Kentucky). Coldstream is a specialty
pharmaceutical contract manufacturer with an emphasis on clinical trial to commercial-scale
manufacturing of sterile liquid and lyophilized parenterals and injectables. Coldstream has
developed differentiated expertise to formulate and manufacture high potency and cytotoxic
compounds including Antibody Drug Conjugates (ADCs). The company operates from a FDA
approved facility located in Lexington, Kentucky, USA. Revenues of Coldstream over the last
three years are ~ USD 14 million (2014E), USD ~13 million (2013) and USD ~9 million
(2012). Coldstream currently employs 91 people.


Commenting on the acquisition Mr. Vivek Sharma, CEO of PEL’s Pharma Solutions business
said “Coldstream is a very high quality operation and has been able to build significant
customer relationships and track record for sterile products. We see this as a great platform
for growth in our Pharma Solutions business. This acquisition allows PEL to move further into
the injectable market segment and should have strong synergy with our existing Pharma
Solutions business. Our strong capabilities in sterile product development and in ADC
product segment will allow us to offer an integrated solution to our customers.”


Bill Wedlake, President of PEL’s Pharma Solutions Formulations business added, “We have
been impressed by the quality of the people at Coldstream and their success in both
attracting high quality business and also their track record in quality. Coldstream’s use of
isolator technology is impressive and provides a foundation for expansion of the facility to provide large scale commercial manufacturing including production of highly potent
compounds.”

Posted on Fri, Jan 23, 2015 @ 05:10 PM by Kathy Sue Bennett in lyophilization, in parenteral manufacturing, in parenteral development, in sterile manufacturing, in antibody drug conjugates

Kathy Sue Bennett

Written by Kathy Sue Bennett

Subscribe to Email Updates